Aura Biosciences, Inc. Logo

Aura Biosciences, Inc.

Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.

AURA | US

Overview

Corporate Details

ISIN(s):
US05153U1079
LEI:
Country:
United States of America
Address:
80 GUEST STREET, 2135 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing a novel class of targeted cancer therapies. The company's proprietary Virus-Like Drug Conjugate (VDC) platform uses Virus-Like Particles (VLPs) to selectively target and destroy solid tumor cells while aiming to preserve healthy tissue. Aura's initial focus is on indications with significant unmet medical needs, particularly in ocular and urologic oncology. Its lead clinical program is being evaluated as a potential first-line treatment for early-stage choroidal melanoma, a rare eye cancer where current treatments often result in vision loss.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aura Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aura Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aura Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Xintela AB Logo
Develops stem cell therapies for osteoarthritis and venous leg ulcers using proprietary technology.
Sweden
XINT
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY
YD Bio Ltd Logo
Developing blood-based cancer detection and regenerative therapies for biopharma partners.
United States of America
YDES
YUHAN CORPORATION Logo
A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.
South Korea
000100
YUKI GOSEI KOGYO CO.,LTD. Logo
Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.
Japan
4531
Zai Lab Ltd Logo
Global biopharma firm developing therapies for oncology, immunology, neuroscience & infectious diseases.
United States of America
ZLAB
Zealand Pharma Logo
Developing innovative peptide medicines for metabolic and inflammatory diseases.
Denmark
ZEAL
Zelluna ASA Logo
Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.
Norway
ULTI
Zenas BioPharma, Inc. Logo
Clinical-stage biopharma developing immunology-based therapies for autoimmune diseases.
United States of America
ZBIO

Talk to a Data Expert

Have a question? We'll get back to you promptly.